BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Glucose Reduction by Early Acarbose Treatment in Basal Insulin
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 124
- Registration Number
- NCT00970528
Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America
Completed
- Conditions
- Hemophilia ABlood Coagulation Disorders
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 105
- Registration Number
- NCT00969319
Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan
Phase 1
Completed
- Conditions
- Pharmacokinetics
- Interventions
- Drug: Naprelan, (BAY H6689)Drug: Naproxen Sodium, (BAY H6689)
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 28
- Registration Number
- NCT00969449
Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68
- Registration Number
- NCT00963833
Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold
Phase 3
Completed
- Conditions
- Common Cold
- Interventions
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 833
- Registration Number
- NCT00963443
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 57
- Registration Number
- NCT00962611
Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients
Phase 1
Completed
- Conditions
- Neoplasm
- Interventions
- Drug: F-18 (BAY85-8050)
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT00961831
Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Ciprofloxacin (PulmoSphere, BAYQ3939)Drug: Placebo
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19
- Registration Number
- NCT00961038
Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT00960258
Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ZK 245186Drug: Placebo (vehicle ointment)
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64
- Registration Number
- NCT00944632
- Locations
- 🇿🇦
PAREXEL International (Bloemfontein), Bloemfontein, South Africa
🇿🇦PAREXEL International (George), George, South Africa
🇿🇦PAREXEL International (Port Elizabeth), Newton Park, South Africa
© Copyright 2025. All Rights Reserved by MedPath